News Related to MAT2A Inhibitor

Related coverage linked through entity extraction aliases.

Gilead Sciences secures $1.5 billion licensing deal for cancer candidate GH31

Mar 20, 2026

Gilead Sciences has agreed a global licensing deal worth up to $1.5 billion with China's Genhouse Bio for its synthetic lethal cancer candidate GH31, a MAT2A inhibitor with IND clearance in the USA and China.

Two Biotech Companies Report 2025 Financial Results and Pipeline Progress

Feb 26, 2026

Edgewise Therapeutics and IDEAYA Biosciences released annual financial reports detailing clinical trial progress and strategic initiatives. Both companies are advancing multiple clinical-stage programs while managing significant operating expenses.